1240390-28-6

Basic information

• Product Name: 2,4-di-chloropyrimidine 5-carboxylic acid amide
• Synonyms: 2,4-di-chloropyrimidine 5-carboxylic acid amide;2,4-dichloropyriMidine-5-carboxaMide;2,4-Dichloro-5-pyrimidinecarboxamide;5-aMinocarbonyl-2,4-dichloropyriMidine;5-Carbamoyl-2,4-dichloropyrimidine, 5-Carbamoyl-2,4-dichloro-1,3-diazine
• CAS NO: 1240390-28-6
• Molecular Formula: C₅H₃Cl₂N₃O
• Molecular Weight: 192
• EINECS: 1308068-626-2
• Mol File: 1240390-28-6.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 364℃
• Flash Point: 174℃
• Appearance: /
• Density: 1.620
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 12.74±0.50(Predicted)
• CAS DataBase Reference: 2,4-di-chloropyrimidine 5-carboxylic acid amide(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-di-chloropyrimidine 5-carboxylic acid amide(1240390-28-6)
• EPA Substance Registry System: 2,4-di-chloropyrimidine 5-carboxylic acid amide(1240390-28-6)

Safety Data

• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 1240390-28-6(Hazardous Substances Data)

Usage

General Description

2,4-di-chloropyrimidine 5-carboxylic acid amide is a chemical compound with potential applications in the pharmaceutical and agricultural industries. It is a derivative of pyrimidine, a six-membered heterocyclic compound containing two nitrogen atoms, and it contains two chlorine atoms at the 2 and 4 positions. The carboxylic acid amide functional group allows for the compound to participate in various chemical reactions, making it a versatile building block for the synthesis of other compounds. This chemical is of interest for its potential as a precursor in the production of pharmaceuticals, herbicides, and pesticides, as well as in the development of new materials and the study of organic chemistry. Additionally, its unique structure and properties make it a valuable compound for research and industrial applications.

InChI:InChI=1S/C5H3Cl2N3O/c6-3-2(4(8)11)1-9-5(7)10-3/h1H,(H2,8,11)

Upstream product

• 23945-44-0 2,4-dihydroxypyrimidine-5-carboxylic acid 
• 2972-52-3 2,4-dichloropyrimidine-5-carbonyl chloride 

Downstream Products

• 1240390-29-7 2-chloro-4-[(4-methylphenyl)amino]-5-pyrimidinecarboxamide 
• 1254214-38-4 2-chloro-4-(1-phenylethylamino)pyrimidine-5-carboxamide 

Relevant articles and documents

JNK inhibitor as well as pharmaceutical composition and application thereof

The invention provides a compound represented by a formula (I), racemates, stereoisomers, tautomers, isotope markers, solvates, polymorphic substances, nitrogen oxides, or pharmaceutically acceptablesalts thereof, and application as a JNK inhibitor. The invention also provides a preparation method of the compound shown in the formula (I), a pharmaceutical composition containing the compound shownin the formula (I), and application of the compound shown in the formula (I) to preparation of a medicine, and the medicine is used for treating diseases which can be treated by inhibiting the activity of JNK.

SYNTHESIS OF CERDULATINIB

The present disclosure provides processes for the preparation of cerdulatinib, which is of formula (I): Formula (I) or a salt thereof. The disclosure also provides intermediates and processes for the preparation of the intermediates useful in the preparation of cerdulatinib or a salt thereof.

Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation

First-generation epidermal growth factor receptor (EGFR) inhibitors, gefitinib and erlotinib, have achieved initially marked clinical efficacy for nonsmall cell lung cancer (NSCLC) patients with EGFR activating mutations. However, their clinical benefit was limited by the emergence of acquired resistance mutations. In most cases (approximately 60%), the resistance was caused by the secondary EGFR T790M gatekeeper mutation. Thus, it is still desirable to develop novel third-generation EGFR inhibitors to overcome T790M mutation while sparing wild-type (WT) EGFR. Herein, a series of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives were designed and synthesized, among which the most potent compound 20g not only demonstrated significant inhibitory activity and selectivity for EGFRL858R/T790M and H1975 cells in vitro but also displayed outstanding antitumor efficiency in H1975 xenograft mouse model. The encouraging mutant-selective results at both in vitro and in vivo levels suggested that 20g might be used as a promising lead compound for further structural optimization as potent and selective EGFRL858R/T790M inhibitors.